The design, synthesis, SAR, and biological profile of a substituted 4-morpholine sulfonamide series of γ-secretase inhibitors (GSIs) were described. In several cases, the resulting series of GSIs reduced CYP liabilities and improved γ-secretase inhibition activity compared to our previous research series. Selected compounds demonstrated significant reduction of amyloid-β (Aβ) after acute oral dosing in a transgenic animal model of Alzheimer's disease (AD).
Keywords: Alzheimer's disease; substituted 4-morpholine sulfonamide; γ-secretase inhibitor.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.